XTLB — XTL Biopharmaceuticals Ltd.

XTLB closed at $2.02 (+2.54%) on Oct 23, 2026. Float: 1.3M shares. Latest SEC filing: 6-K on Oct 14, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for XTLB in the TickerWise workspace.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: IL
• Exchange: NASDAQ
• Employees: 10
• Website: https://www.xtlbio.com

Latest SEC filings for XTLB

• 2026-10-146-K
• 2026-07-216-K
• 2026-06-306-K
• 2026-06-3020-F
• 2026-06-296-K
• 2026-05-226-K
• 2026-05-156-K
• 2026-05-076-K
• 2026-04-30NT 20-F
• 2026-04-296-K

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.